Therapy with interleukin-2 induces the systemic release of phospholipase-A2 |
| |
Authors: | Gert Jan Wolbink Caspar Schalkwijk Joke W. Baars John Wagstaff Henk van den Bosch C. Erik Hack |
| |
Affiliation: | (1) Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands;(2) Laboratory for Clinical and Experimental Immunology, University of Amsterdam, Amsterdam, The Netherlands;(3) Centre for Biomembranes and Lipid Enzymology, University of Utrecht, Utrecht, The Netherlands;(4) Department of Oncology, Free University Hospital, Amsterdam, The Netherlands;(5) Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands |
| |
Abstract: | Therapy with interleukin-2 (IL-2) induces remissions in some forms of cancer. This treatment however, is accompanied by side-effects which, in part, may be mediated by the formation of eicosanoids and plateletactivating factor. We investigated the systemic release of phospholipase A2 (PLA2), a rate-limiting enzyme in the formation of these lipid mediators, in patients receiving IL-2. In a pilot study of 4 patients we observed an increase in PLA2 activity in serial plasma samples obtained during the first day after a bolus infusion of IL-2, which increase closely correlated with that of antigen levels of secretory phospholipase A2 (sPLA2) as measured by enzyme-linked immunosorbent assay (r=0.92;P<0.001). In 20 patients, receiving 12×106–18×106 IU IL-2/m2, we then investigated the course of antigenic levels of sPLA2 in relation to those of the cytokines tumour necrosis factor (TNF) and interleukin-6 (IL-6) (both cytokines may induce sPLA2 in vivo). From 4 h on, sPLA2 levels significantly increased, reaching a peak 24 h after the IL-2 infusion. Subsequent IL-2 infusions even induced a further increase of sPLA2. This increase of sPLA2 was presumably not due to a direct effect of IL-2 on, for example, hepatocytes, since this cytokine, in contrast to IL-1, IL-6, TNF and interferon , was not able to induce the synthesis of sPLA2 by Hep G2 cells in vitro. Consistent with this, plasma levels of TNF and IL-6 in the patients rose, reaching peak levels before a zenith of sPLA2 occurred, i.e at 2 h and 4 h after the start of the IL-2 infusion respectively. sPLA2 levels significantly correlated with the development of the side-effects increase in body weight (r=0.49;P<0.0001) and decrease in mean arterial blood pressure (r=0.40;P<0.0001). Moreover, maximum sPLA2 levels induced by IL-2 were higher in patients who had progressive disease after therapy than in patients who had stable disease or a partial response. |
| |
Keywords: | Interleukin-2 (IL-2) Interleukin-6 (IL-6) Tumour necrosis factor (TNF) Phospholipase A2 (PLA2) Cancer |
本文献已被 SpringerLink 等数据库收录! |
|